NO2022019I1 - Eribulin eller et farmasøytisk akseptabelt salt derav - forlenget SPC - Google Patents

Eribulin eller et farmasøytisk akseptabelt salt derav - forlenget SPC

Info

Publication number
NO2022019I1
NO2022019I1 NO2022019C NO2022019C NO2022019I1 NO 2022019 I1 NO2022019 I1 NO 2022019I1 NO 2022019 C NO2022019 C NO 2022019C NO 2022019 C NO2022019 C NO 2022019C NO 2022019 I1 NO2022019 I1 NO 2022019I1
Authority
NO
Norway
Prior art keywords
eribulin
spc
extended
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
NO2022019C
Other languages
English (en)
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22219026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2022019(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of NO2022019I1 publication Critical patent/NO2022019I1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
NO2022019C 1998-06-17 2022-06-03 Eribulin eller et farmasøytisk akseptabelt salt derav - forlenget SPC NO2022019I1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8968298P 1998-06-17 1998-06-17

Publications (1)

Publication Number Publication Date
NO2022019I1 true NO2022019I1 (no) 2022-06-03

Family

ID=22219026

Family Applications (5)

Application Number Title Priority Date Filing Date
NO20006316A NO328280B1 (no) 1998-06-17 2000-12-12 Makrocykliske analoger
NO20093217A NO331183B1 (no) 1998-06-17 2009-10-26 Farmasoytisk preparat omfattende en halokondrinanalog eller et farmasoytisk salt derav og en farmasoytisk akseptabel baerer
NO2011018C NO2011018I1 (no) 1998-06-17 2011-09-16 Eribulin og farmasøytisk akseptable salter derav
NO2011026C NO2011026I2 (no) 1998-06-17 2011-12-14 Eribulin eller et farmasøytisk akseptabelt salt derav
NO2022019C NO2022019I1 (no) 1998-06-17 2022-06-03 Eribulin eller et farmasøytisk akseptabelt salt derav - forlenget SPC

Family Applications Before (4)

Application Number Title Priority Date Filing Date
NO20006316A NO328280B1 (no) 1998-06-17 2000-12-12 Makrocykliske analoger
NO20093217A NO331183B1 (no) 1998-06-17 2009-10-26 Farmasoytisk preparat omfattende en halokondrinanalog eller et farmasoytisk salt derav og en farmasoytisk akseptabel baerer
NO2011018C NO2011018I1 (no) 1998-06-17 2011-09-16 Eribulin og farmasøytisk akseptable salter derav
NO2011026C NO2011026I2 (no) 1998-06-17 2011-12-14 Eribulin eller et farmasøytisk akseptabelt salt derav

Country Status (23)

Country Link
US (4) US6214865B1 (no)
EP (4) EP1087960B1 (no)
JP (1) JP4454151B2 (no)
KR (1) KR100798600B1 (no)
CN (1) CN1216051C (no)
AT (1) ATE502932T1 (no)
AU (1) AU762998B2 (no)
BE (1) BE2011C028I2 (no)
BR (1) BRPI9911326B8 (no)
CA (3) CA2755266C (no)
CY (2) CY1111516T1 (no)
DE (2) DE69943296D1 (no)
DK (1) DK1087960T3 (no)
FR (1) FR11C0038I2 (no)
HK (1) HK1035534A1 (no)
HU (1) HU227912B1 (no)
IL (1) IL139960A0 (no)
LU (1) LU91854I2 (no)
NO (5) NO328280B1 (no)
NZ (1) NZ508597A (no)
PT (1) PT1087960E (no)
WO (1) WO1999065894A1 (no)
ZA (1) ZA200007159B (no)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100798600B1 (ko) 1998-06-17 2008-01-28 에자이 가부시키가이샤 마크로시클릭 유사체 및 그들의 이용 및 제조방법
US8097648B2 (en) * 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
DE10037310A1 (de) * 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
AU2003224644A1 (en) * 2002-02-27 2003-09-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
IL163868A0 (en) 2002-03-22 2005-12-18 Eisai Co Ltd Hermiasterlin derivatives and uses thereof
US20050075395A1 (en) * 2003-05-28 2005-04-07 Gary Gordon Continuous dosing regimen
WO2004105794A2 (en) * 2003-05-29 2004-12-09 Abbott Laboratories Continuous dosing regimen with abt-751
EP1653953A4 (en) * 2003-07-29 2010-05-05 Eisai R&D Man Co Ltd METHOD AND DEVICES FOR THE MEDICINAL PRODUCTION
CA2822994C (en) * 2004-06-03 2016-09-27 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of halichondrin b
ES2748200T3 (es) 2004-06-03 2020-03-13 Eisai R&D Man Co Ltd Productos intermedios para la preparación de halicondrina B
US20060045846A1 (en) * 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
US20060154312A1 (en) * 2004-12-09 2006-07-13 Sergei Agoulnik Tubulin isotype screening in cancer therapy using halichondrin B analogs
RU2489437C2 (ru) 2007-10-03 2013-08-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Промежуточные соединения и способы синтеза аналогов галихондрина в
WO2009124237A1 (en) 2008-04-04 2009-10-08 Eisai R&D Management Co., Ltd. Halichondrin b analogs
EP2415464B1 (en) 2009-03-30 2017-05-10 Eisai R&D Management Co., Ltd. Method for producing liposome composition
KR101495951B1 (ko) 2009-03-30 2015-02-25 에자이 알앤드디 매니지먼트 가부시키가이샤 리포솜 조성물
RU2476216C1 (ru) * 2009-03-30 2013-02-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Липосомальная композиция
EP2420504B1 (en) * 2009-04-14 2014-01-15 Nissan Chemical Industries, Ltd. Method for producing tetrahydropyran compound and intermediate thereof
EP2528914B1 (en) 2010-01-26 2014-06-11 Eisai R&D Management Co., Ltd. Furo[3,2-b]pyrane derivatives useful in the synthesis of halichondrin b analogs
US9637795B2 (en) 2011-03-18 2017-05-02 Eisai R&D Management Co., Ltd. Methods and compositions for predicting response to eribulin
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
ES2705950T3 (es) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
CA2857385A1 (en) 2011-11-30 2013-06-06 Alphora Research Inc. Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene
JP2015501818A (ja) 2011-12-16 2015-01-19 アルフォラ リサーチ インコーポレイテッドＡｌｐｈｏｒａ Ｒｅｓｅａｒｃｈ Ｉｎｃ． ３−（（２ｓ，５ｓ）−４−メチレン−５−（３−オキソプロピル）テトラヒドロフラン−２−イル）プロパノール誘導体およびそれらの有用な中間体を調製する方法
AU2012363334B2 (en) * 2011-12-29 2017-02-02 Alphora Research Inc. 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl) tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation
EP2831082B1 (en) * 2012-03-30 2019-02-20 Sandoz AG Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein
AU2013353745A1 (en) 2012-12-04 2015-06-11 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of breast cancer
CA2909209A1 (en) 2013-05-15 2014-11-20 Alphora Research Inc. 3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof
AU2014299699B2 (en) 2013-06-26 2019-10-10 Eisai R&D Management Co., Ltd. Use of eribulin and lenvatinib as combination therapy for treatment of cancer
AU2014286880B2 (en) * 2013-07-03 2017-12-14 Sandoz Ag Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein including intermediates containing -SO2-(p-TOLYL) groups
CN103483352A (zh) * 2013-10-18 2014-01-01 李友香 抗肿瘤的药用原料药
EP3066102B1 (en) 2013-11-04 2020-02-26 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b
US9303039B2 (en) 2013-12-06 2016-04-05 Eisai R&D Management Co., Ltd. Methods useful in the synthesis of halichondrin B analogs
CN104860978A (zh) * 2014-02-20 2015-08-26 正大天晴药业集团股份有限公司 软海绵素b类似物的合成中间体
TW201617326A (zh) 2014-03-06 2016-05-16 Ａｌｐｈｏｒａ研發股份有限公司 （ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物
AU2015267099B2 (en) * 2014-05-28 2020-08-27 Eisai R&D Management Co., Ltd Use of eribulin in the treatment of cancer
JP2017520586A (ja) 2014-06-30 2017-07-27 プレジデント アンド フェローズ オブ ハーバード カレッジ ハリコンドリン類似体の合成およびその使用
SI3524595T1 (sl) 2014-08-28 2022-10-28 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistosti in postopek njegove proizvodnje
US10208058B2 (en) 2014-09-09 2019-02-19 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts and intermediates thereof
CN105713031B (zh) * 2014-12-05 2021-05-07 正大天晴药业集团股份有限公司 一种用于制备艾日布林的中间体及其制备方法
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CA2978311A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and eribulin for treating cancer
WO2016176560A1 (en) 2015-04-30 2016-11-03 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
MX2017014237A (es) * 2015-05-07 2018-09-17 Eisai R&D Man Co Ltd Reacciones de macro-ciclizacion e intermediarios y otros fragmentos utiles en la sintesis de macrolidos de halicondrina.
US10597401B2 (en) 2015-05-08 2020-03-24 Albany Molecular Research, Inc. Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
JP6786610B2 (ja) * 2016-02-12 2020-11-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 エリブリンの合成における中間体および関連する合成方法
WO2017188350A1 (ja) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
BR112018074287A2 (pt) 2016-05-26 2019-06-18 Dr Reddys Laboratories Ltd processo para preparação de eribulina e intermediários da mesma
CN109641917B (zh) 2016-06-30 2022-06-14 卫材R&D管理有限公司 可用于合成软海绵素大环内酯类及其类似物的普林斯反应和中间体
AU2017342462A1 (en) 2016-10-14 2019-05-02 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and eribulin for treating urothelial cancer
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
KR20190084065A (ko) * 2016-11-23 2019-07-15 닥터 레디스 레보러터리즈 리미티드 에리불린 및 그 중간체의 제조방법
JP6920699B2 (ja) * 2017-01-02 2021-08-18 ヨンスン ファイン ケミカル カンパニー，リミテッド エリブリンメシル酸塩の製造中間体及びその製造方法
KR101991710B1 (ko) 2017-12-14 2019-06-21 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
KR101880939B1 (ko) 2017-01-02 2018-08-17 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
CN108341738B (zh) * 2017-01-24 2022-10-21 江苏恒瑞医药股份有限公司 用于制备艾日布林的方法及其中间体
CN108341828B (zh) * 2017-01-24 2021-04-06 江苏恒瑞医药股份有限公司 用于制备艾日布林的方法及其中间体
HRP20221385T1 (hr) 2017-04-05 2023-01-06 President And Fellows Of Harvard College Makrociklički spoj i njegova uporaba
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
JP7370313B2 (ja) 2017-07-06 2023-10-27 プレジデント アンド フェローズ オブ ハーバード カレッジ ハリコンドリンの合成
US20190046513A1 (en) 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
CN109694379B (zh) * 2017-10-24 2020-09-11 江苏恒瑞医药股份有限公司 用于制备艾日布林的中间体及其制备方法
EP3712141B1 (en) * 2017-11-09 2023-07-12 Yonsung Fine Chemical Co., Ltd. Intermediate for preparing eribulin mesylate and method for preparing same
JP7353281B2 (ja) 2017-11-15 2023-09-29 プレジデント アンド フェローズ オブ ハーバード カレッジ 大環状化合物およびそれらの使用
US11419856B2 (en) 2017-11-20 2022-08-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
US11008296B2 (en) 2017-11-21 2021-05-18 Natco Pharma Limited Intermediates for the preparation of eribulin thereof
KR20200105877A (ko) 2018-01-03 2020-09-09 에자이 알앤드디 매니지먼트 가부시키가이샤 할리콘드린 마크롤리드 및 그의 유사체의 합성에 유용한 프린스 반응 및 화합물
WO2019211877A1 (en) 2018-05-03 2019-11-07 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin b
WO2020008382A1 (en) * 2018-07-04 2020-01-09 Dr. Reddy’S Laboratories Limited Process for preparation of eribulin and intermediates thereof
WO2020016847A2 (en) * 2018-07-20 2020-01-23 Dr. Reddy’S Laboratories Limited Purification process for preparation of eribulin and intermediates thereof
US20210340156A1 (en) * 2018-10-09 2021-11-04 Dr. Reddy's Laboratories Limited Process for preparation of eribulin and intermediates thereof
US11447499B2 (en) 2019-06-14 2022-09-20 Rk Pharma Inc. Process for the preparation of eribulin mesylate intermediate
JP2022537785A (ja) 2019-06-21 2022-08-29 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ ホモプロパルギルアルコールを調製するための化学酵素的プロセス
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
KR20220095197A (ko) 2019-11-07 2022-07-06 에자이 알앤드디 매니지먼트 가부시키가이샤 항-메소텔린 에리불린 항체-약물 컨쥬게이트 및 이용 방법
CN113135876B (zh) * 2020-01-16 2024-05-17 南通诺泰生物医药技术有限公司 艾日布林及其中间体的制备方法
US20230144203A1 (en) * 2020-01-22 2023-05-11 Shanghai Senhui Medicine Co., Ltd. Drug conjugate of eribulin derivative, preparation method therefor and application thereof in medicine
KR102377262B1 (ko) 2020-05-11 2022-03-22 연성정밀화학(주) 결정성 에리불린 염
IL279168B (en) * 2020-12-02 2022-04-01 Finetech Pharmaceutical Ltd A process for the preparation of eribulin
CN113354659B (zh) 2021-06-08 2022-04-08 江苏慧聚药业股份有限公司 甲磺酸艾日布林的合成
TW202310878A (zh) * 2021-07-22 2023-03-16 大陸商上海森輝醫藥有限公司 艾日布林衍生物的藥物偶聯物
WO2023212746A2 (en) * 2022-04-30 2023-11-02 William Marsh Rice University A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin b
CN118356507A (zh) * 2023-01-17 2024-07-19 成都百利多特生物药业有限责任公司 一种艾日布林类药物的偶联物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
US5338865A (en) 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
GB9206244D0 (en) * 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
US5426194A (en) * 1993-01-19 1995-06-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 1
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
KR100798600B1 (ko) * 1998-06-17 2008-01-28 에자이 가부시키가이샤 마크로시클릭 유사체 및 그들의 이용 및 제조방법
ES2748200T3 (es) 2004-06-03 2020-03-13 Eisai R&D Man Co Ltd Productos intermedios para la preparación de halicondrina B
RU2489437C2 (ru) 2007-10-03 2013-08-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Промежуточные соединения и способы синтеза аналогов галихондрина в
RU2010118063A (ru) 2007-11-16 2011-12-27 ЭЙСАЙ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. (JP) Новое промежуточное соединение для синтеза аналога галихондрина в и новая реакция десульфонилирования, применяемая для получения промежуточного соединения
WO2009124237A1 (en) 2008-04-04 2009-10-08 Eisai R&D Management Co., Ltd. Halichondrin b analogs
EP2528914B1 (en) 2010-01-26 2014-06-11 Eisai R&D Management Co., Ltd. Furo[3,2-b]pyrane derivatives useful in the synthesis of halichondrin b analogs

Also Published As

Publication number Publication date
DE122011100031I1 (de) 2011-12-15
US6214865B1 (en) 2001-04-10
HUP0103357A3 (en) 2002-10-28
JP2002518384A (ja) 2002-06-25
FR11C0038I1 (fr) 2011-10-14
BR9911326B1 (pt) 2015-01-06
LU91854I2 (fr) 2011-10-17
KR20010083050A (ko) 2001-08-31
RU2245335C2 (ru) 2005-01-27
NO20006316D0 (no) 2000-12-12
HU227912B1 (en) 2012-05-29
EP1087960A1 (en) 2001-04-04
AU4573999A (en) 2000-01-05
CA2632433C (en) 2012-02-07
CY2011010I2 (el) 2014-04-09
US6469182B1 (en) 2002-10-22
WO1999065894A1 (en) 1999-12-23
KR100798600B1 (ko) 2008-01-28
EP2272839A1 (en) 2011-01-12
EP2272840B1 (en) 2012-08-22
EP1087960A4 (en) 2004-12-01
AU762998C (en) 2000-01-05
US20110172446A1 (en) 2011-07-14
CA2755266A1 (en) 1999-12-23
BRPI9911326B8 (pt) 2021-05-25
NO20093217L (no) 2001-02-15
NZ508597A (en) 2004-01-30
NO331183B1 (no) 2011-10-24
CA2755266C (en) 2014-08-12
NO20006316L (no) 2001-02-15
HK1035534A1 (en) 2001-11-30
EP2277873A1 (en) 2011-01-26
CA2335300C (en) 2008-10-07
NO2011026I2 (no) 2012-06-11
HUP0103357A2 (hu) 2002-01-28
NO2011018I1 (no) 2011-09-26
CY1111516T1 (el) 2014-04-09
FR11C0038I2 (fr) 2013-01-11
ZA200007159B (en) 2001-12-04
CA2335300A1 (en) 1999-12-23
CA2632433A1 (en) 1999-12-23
EP1087960B1 (en) 2011-03-23
ATE502932T1 (de) 2011-04-15
EP2272839B1 (en) 2012-08-22
DE69943296D1 (de) 2011-05-05
NO2011026I1 (no) 2012-01-09
BR9911326A (pt) 2001-04-03
IL139960A0 (en) 2002-02-10
CN1216051C (zh) 2005-08-24
NO328280B1 (no) 2010-01-25
AU762998B2 (en) 2003-07-10
CY2011010I1 (el) 2014-04-09
EP2272840A1 (en) 2011-01-12
DK1087960T3 (da) 2011-06-14
US8148554B2 (en) 2012-04-03
EP2277873B1 (en) 2012-05-30
US6365759B1 (en) 2002-04-02
PT1087960E (pt) 2011-06-17
JP4454151B2 (ja) 2010-04-21
BE2011C028I2 (en) 2018-08-24
CN1312804A (zh) 2001-09-12

Similar Documents

Publication Publication Date Title
NO2022019I1 (no) Eribulin eller et farmasøytisk akseptabelt salt derav - forlenget SPC
NO2018005I1 (no) tivozanib eller et salt eller solvat derav
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
FI950309A (fi) Proliiniamidijohdannaisia
CY1106522T1 (el) Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
LU91210I2 (fr) Emodepside & Praziquantel ainsi que leurs dérivés pharmaceutiqement acceptables (PROFENDER)
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
DK0903347T3 (da) Hidtil ukendte cyclodepsipeptid PF1022-derivater
ES2093037T3 (es) Derivados de beta-lactama y su preparacion.
FI952420A (fi) Glukopyranosidibentsotiofeenit
FI911138A (fi) Ny substituerad aminfoerening och foerfarande foer dess framstaellning.
DK0520372T3 (da) Inositol-phosphat-analoger som calciumantagonistiske stoffer
DK0420224T3 (da) Anthihepatopatisk middel
FI901277A0 (fi) 2,5,6,7-tetranor-4,8-inter-m-fenylen pg1z-derivativ.
PT952157E (pt) Derivados 9a, 11b-desidro de 9-oxima-3-ceto-6-o-metileritromicina
FI941850A0 (fi) Uusi yhdiste, joka on leustroduksiini H, sen valmistus ja terapeuttinen käyttö
DK0760375T3 (da) Antitumor-indolopyrrolocarbazolderivater
DK1065206T3 (da) Tetrazolylalkylindol-forbindelser som anti-inflammatoriske og analgetiske midler
CY1110529T1 (el) Παρασκευη ν-υποκατεστημενων 2,7-διαλκυλο-4-υδροξυ-5-αμινο-8-αρυλοοκτανοϋλαμιδιων